These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Genetic Basis of Inflammatory Demyelinating Diseases of the Central Nervous System: Multiple Sclerosis and Neuromyelitis Optica Spectrum. Ortiz GG; Torres-Mendoza BMG; Ramírez-Jirano J; Marquez-Pedroza J; Hernández-Cruz JJ; Mireles-Ramirez MA; Torres-Sánchez ED Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510224 [TBL] [Abstract][Full Text] [Related]
9. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Weber MS; Derfuss T; Metz I; Brück W Ther Adv Neurol Disord; 2018; 11():1756286418762083. PubMed ID: 29623106 [TBL] [Abstract][Full Text] [Related]
10. Modified models to distinguish central nervous system demyelinating diseases with brain lesions. Chen B; Qin C; Ji S; Tian D; Zhang M; Bu B Mult Scler Relat Disord; 2021 Jul; 52():102965. PubMed ID: 33905981 [TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690 [TBL] [Abstract][Full Text] [Related]
12. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes. Alves Do Rego C; Collongues N Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427 [TBL] [Abstract][Full Text] [Related]
14. [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification]. Aktas O; Kümpfel T Nervenarzt; 2021 Apr; 92(4):307-316. PubMed ID: 33728474 [TBL] [Abstract][Full Text] [Related]
15. The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis. Messina S; Mariano R; Geraldes R; Kim SH; Satukijcha C; Vecchio D; Chua YY; Taylor J; George N; Cavey A; Diaz AR; Reeve S; Everett R; De Luca G; Leite MI; Kim HJ; Palace J Mult Scler Relat Disord; 2021 Apr; 49():102773. PubMed ID: 33540279 [TBL] [Abstract][Full Text] [Related]
16. Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD). Kwon YN; Kim B; Ahn S; Seo J; Kim SB; Yoon SS; Sung JJ; Choi YS; Kim SM J Neuroimmunol; 2020 Nov; 348():577361. PubMed ID: 32919144 [TBL] [Abstract][Full Text] [Related]
17. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders? Di Pauli F; Berger T Front Immunol; 2018; 9():2753. PubMed ID: 30555462 [TBL] [Abstract][Full Text] [Related]
18. Increasing role of imaging in differentiating MS from non-MS and defining indeterminate borderline cases. Juryńczyk M; Jakuszyk P; Kurkowska-Jastrzębska I; Palace J Neurol Neurochir Pol; 2022; 56(3):210-219. PubMed ID: 34664709 [TBL] [Abstract][Full Text] [Related]
19. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis. Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694 [TBL] [Abstract][Full Text] [Related]